Current and Future Insights in H. pylori Eradication Regimens: The Need of Tailoring Therapy

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)

Volume 23, 46 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Design

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 73rd of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

William A. Banks
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.052
5 - Year: 3.132

Current and Future Insights in H. pylori Eradication Regimens: The Need of Tailoring Therapy

Current Pharmaceutical Design, 20(28): 4521-4532.

Author(s): Vasilios Papastergiou, Sotirios D. Georgopoulos and Stylianos Karatapanis.

Affiliation: 10 Kalopetras Str, Rhodes, 85100, Greece.


Treatment of Helicobacter pylori (H. pylori) infection is crucial for the management of prevalent digestive and more recently also extra-digestive disorders. Rising prevalence of clarithromycin resistance worldwide has accounted for a dramatic decline in the efficacy of standard triple therapies, which should not be prescribed, unless local clarithromycin-resistance is low (<20%) or culture confirms susceptibility to this antibiotic (i,e,; as tailored treatments). Bismuth-quadruple, sequential, non-bismuth quadruple (concomitant), dual-concomitant (hybrid), and levofloxacin-based regimens have been shown to overcome clarithromycin resistance and are now preferred empirical treatments achieving improved eradication rates (>90% in per protocol analysis). In the future, empiric use of both clarithromycin and levofloxacin is likely to become steadily more challenging as even these novel eradication therapies may be prone to the effect of increasing antibiotic resistance. Tailored treatment based on the individual characterization of H. pylori therapeutic susceptibility appears to be a reasonable future alternative, currently limited by the shortcomings of systematically performing H. pylori culture (invasive, expensive, time-consuming). However, recent advances in the genotypic detection of H. pylori susceptibility to antibiotics, and in pharmacogenomics, may represent a breakthrough in our future approach to tailored therapy. Until then, efforts to optimize empirical treatments should continue.


Antibiotic resistance, bismuth-quadruple, concomitant, eradication therapy, helicobacter pylori, sequential.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 20
Issue Number: 28
First Page: 4521
Last Page: 4532
Page Count: 12
DOI: 10.2174/13816128113196660726
Price: $58
4th Microbiome R&D and Business Collaboration Forum: EuropeRNA Therapeutics 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science